Sanofi’s Altuviiio receives FDA approval to treat haemophilia A
Pharmaceutical Technology
FEBRUARY 24, 2023
Sanofi has received approval from the US Food and Drug Administration (FDA) for its Altuviiio [Antihemophilic Factor (Recombinant) , Fc-VWF-XTEN Fusion Protein-ehtl], to treat a type of inherited bleeding disorder known as haemophilia A. Earlier, they received treatment with factor VIII replacement therapy. median ABR.
Let's personalize your content